Navigation Links
Pharma IQ's Drug Recalls Industry Outline
Date:8/24/2012

LONDON, August 24, 2012 /PRNewswire/ --

Pharma IQ has just produced the Drug Recalls Industry Outline, where it analyses the challenges and implications of the late stage development failures. Pharma IQ had a quick look back over the last few years to see a timeline of drug failures and recalls at the late stages of development.

'Some of the key time saving strategies and information sources to make these decisions are trial design approaches, imaging techniques, biomarkers, strategic outsourcing and patient recruitment' says Nicola Ambler, Senior Conference Director, Pharma IQ, who is directing the upcoming Innovation in Phase 1 Clinical Development in Milan this September.

The outline analyses the drug withdrawals in the latter stages. In August 2012, Pfizer and J&J announced they were going to stop the development of the Alzheimer's drug, Bapineuzumab.  In March 2012 AstraZeneca and Targacept announced that their partnered depression drug - TC-5214 - failed at Phase III. The last two of four late-stage studies failed to meet their primary endpoints, eliminating plans for a comeback after the first two Phase III studies also ended in failure. In March 2011 Sanofi-Aventis' lung cancer drug aflibercept failed to meet its primary endpoint in a phase III trial.

The Drug Recalls Industry Outline can be accessed at http://www.phase1clinicaldevelopment.com/news

The Industry Outline was created as a part of the pre-conference preparation for the 3th Innovation in Phase I Clinical Development Forum taking place 17-19 September, 2012 in Milan. The agenda and final speaker line-up feature JW McBlane, Pharmaceutical Assessor, MHRA that will lead the session Early Clinical Studies - A Regulator's Expectations for Complex Protocols and Complex Productsand  Corina Dota, ECG Centre Director, Co-chair Cardiac QT/Arrhythmia Safety Knowledge Group from AstraZeneca presenting the case study Designing and Integrating a Robust Cardiac Safety Strategy.

Other important topics that will be discussed at the event include:

  • Biomarker development and early strategies for patients selection (case study from Roche);
  • Overcoming the internal and external challenges of developing the right biomarker at the right time (open discussion with Lundbeck);
  • Potential impact of ICH guidelines (M3, S9 and S6) on the scientific based non clinical assessment to achieve faster regulatory decisions on anticancer Phase One Clinical Trials (Italian Health Ministry)

To access the full Overview or to find out more about Phase I Clinical Development Forum 2012 please visit http://www.phase1clinicaldevelopment.com/news, email  enquire@iqpc.co.uk or call +44(0)2073689421.

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Joanna Checinska (joanna.checinska@iqpc.co.uk)

Media contact: Joanna, +44(0)20-7368-9421, joanna.checinska@iqpc.co.uk  - Please contact for more information or images.


'/>"/>
SOURCE Pharma IQ
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):